Skip to main content
Premium Trial:

Request an Annual Quote

New York Approves AssureRx's Lab

The story has been corrected to say that certification from New York is for AssureRx's laboratory not its GeneSightRx test.

NEW YORK (GenomeWeb News) – The New York State Department of Health has certified AssureRx's laboratory, allowing residents in the state access to the company's pharmacogenomic test, GeneSightRx.

As a result of the approval, the Mason, Ohio-based company's laboratory is certified to analyze DNA samples for pharmacogenomic testing in all 50 states.

GeneSightRx is for helping determine which psychiatric drugs may be most effective for a patient. The test was launched in late 2009 and combines pharmacogenomic data from scientific and clinical publications, information from drug labels, and the patient's genetic profile. A cheek swab is taken from a patient then analyzed at AssureRx's CLIA-certified laboratory.

As GenomeWeb Daily News' sister publication Pharmacogenomics Reporter said last week, AssureRx has made improvements to the test by adding new therapies on the test panel and launching a mobile device application to give doctors greater flexibility in ordering and viewing test results.

The Scan

Researchers Compare WGS, Exome Sequencing-Based Mendelian Disease Diagnosis

Investigators find a diagnostic edge for whole-genome sequencing, while highlighting the cost advantages and improving diagnostic rate of exome sequencing in EJHG.

Researchers Retrace Key Mutations in Reassorted H1N1 Swine Flu Virus With Avian-Like Features

Mutations in the acidic polymerase-coding gene boost the pathogenicity and transmissibility of Eurasian avian-like H1N1 swine influenza viruses, a PNAS paper finds.

Genome Sequences Reveal Evolutionary History of South America's Canids

An analysis in PNAS of South American canid species' genomes offers a look at their evolutionary history, as well as their relationships and adaptations.

Lung Cancer Response to Checkpoint Inhibitors Reflected in Circulating Tumor DNA

In non-small cell lung cancer patients, researchers find in JCO Precision Oncology that survival benefits after immune checkpoint blockade coincide with a dip in ctDNA levels.